Clough Global Dividend and Income Fund (GLV) News

Table 3A shows more than half billion issued to Phillipe in last FY...guessing we will see more

Cheers!

AIRI>>>>Suggest keeping on your watch lists. With new orders backlog now over $250 Million. Ad to run on CNBC. Just a FYI. HAWK

The chart is churning nicely this week ... Setting up for March.

Buy the dips and sell the rips.

It's coming

For equivalency between Flaskworks and the manual manufacturing method, would NWBO not only need to show a robust immune response within a given period? This is an extremely short duration.

Phillipe current conversion rate is .00026

$NIXX Looking for a strong day as we squeeze the shorts. Zero shares to borrow now!
https://investorshub.advfn.com/uimage/uploads/2025/2/27/hketrNIXX-CTB.png

1. You don't sell Cds into market

A. You sign a convertible note with a discounted price (i.e.duanne phillipe had a 35 discount) usually lowest pps over previous 20 days b/c you gave company cash.

B. After a year, one can convert for free trading shares assuming company

QNRX radar nice news https://ih.advfn.com/stock-market/NASDAQ/quoin-pharmaceuticals-QNRX/stock-news/95526874/quoin-pharmaceuticals-announces-highly-positive

COHR/LITE/ANET- All went down 32% for no reason, and

after blowout reports and guidance. This is why Warren Buffet wants no part of tech stocks. They can crash out of nowhere.

I noticed Steve Lines had exercised 335 042 rights (resulting in 335 042 common shares) as recently as 25 February. Always nice to see him commit to more shares since he is in charge of the entire EA process. The key point here is that even though it might sound like a small amount of shares it migh

AIRI>>>Undervalued, imho. With new orders backlog now over $250 Million. Suggest keeping on your watch lists. Just a FYI. HAWK

Posted 15 mins ago….On February 27, 2025, NLS Pharmaceutics announced new preclinical data for AEX-2, a non-sulfonamide dual orexin receptor agonist, highlighting its potential for treating narcolepsy and related neurological disorders. The findings suggest AEX-2 offers a safer and more targeted alt

On February 27, 2025, NLS Pharmaceutics announced new preclinical data for AEX-2, a non-sulfonamide dual orexin receptor agonist, highlighting its potential for treating narcolepsy and related neurological disorders. The findings suggest AEX-2 offers a safer and more targeted alternative to existing

EDP-323

DDI study just listed yesterday

https://clinicaltrials.gov/study/NCT06847464?term=rsv%20enanta&aggFilters=status:rec&rank=3

ULY: .90 picking up steam

Premarket $2.75.. 3Million market cap Where do you want it to go… Its a sabotage, Cant you see management are all fraud artists
https://www.transcodetherapeutics.com/leadership.html

~~COMPX 2/27/2025~~~~~~~

Previous Close

19075.26 +48.88

19252 BullNBear52
19194 SSKILLZ1

You're a 🤡 

QNRX radar news https://ih.advfn.com/stock-market/NASDAQ/quoin-pharmaceuticals-QNRX/stock-news/95526874/quoin-pharmaceuticals-announces-highly-positive

Gonna be a fun day;)

QNRX radar news https://ih.advfn.com/stock-market/NASDAQ/quoin-pharmaceuticals-QNRX/stock-news/95526874/quoin-pharmaceuticals-announces-highly-positive

AIRI>>>With total backlog going over $250 Million pps has company undervalued, imho. Suggest keeping on your watch lists. Just a FYI. HAWK

And yall are already on a first-name basis

GM LD!!